SUSAN HILSENBECK to Pancreatic Neoplasms
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Pancreatic Neoplasms.
Connection Strength
0.325
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
Score: 0.145
-
Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2010 05 15; 160(2):268-76.
Score: 0.056
-
Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2009 Oct; 156(2):189-98.
Score: 0.051
-
Preoperative prediction of complete resection in pancreatic cancer. J Surg Res. 2008 Jun 15; 147(2):216-20.
Score: 0.048
-
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs. 1997; 15(4):361-4.
Score: 0.022
-
Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2. J Surg Res. 1988 Dec; 45(6):523-30.
Score: 0.003